Cargando…
Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation
Low‐dose aspirin is currently recommended for patients with polycythemia vera (PV), a myeloproliferative neoplasm with increased risk of arterial and venous thromboses. Based on aspirin pharmacodynamics in essential thrombocythemia, a twice‐daily regimen is recommended for patients with PV deemed at...
Autores principales: | Petrucci, Giovanna, Giaretta, Alberto, Ranalli, Paola, Cavalca, Viviana, Dragani, Alfredo, Porro, Benedetta, Hatem, Duaa, Habib, Aida, Tremoli, Elena, Patrono, Carlo, Rocca, Bianca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747129/ https://www.ncbi.nlm.nih.gov/pubmed/36200184 http://dx.doi.org/10.1111/cts.13415 |
Ejemplares similares
-
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
por: Sacco, Monica, et al.
Publicado: (2020) -
Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
por: Tosetto, Alberto, et al.
Publicado: (2021) -
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
por: De Stefano, Valerio, et al.
Publicado: (2018) -
Measurement of Thromboxane Biosynthesis in Health and Disease
por: Patrono, Carlo, et al.
Publicado: (2019) -
Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)